星标 ★ IPO日报 精彩文章第一时间推送 经历数年的波动与调整，全球并购市场在2025年展现出全面回温迹象。其中，我国并购市场迎来根本性的规则重塑，迸发活力，并购上会家数接近翻倍， 重大重组交易量超前六年总和。 步入2026年，随着宏观经济周期的可能转向、科技革命深化、地缘政治格局演变及监管环境持续优化，并购活动有望迎 来更具结构性的增长机遇。 张力制图 政策持续优化 在"十五五"规划关于并购重组的政策表述中，对上市公司并购重组的定位更为积极，其中提出要持续深化并购重组市场改革，支持上市公司转型升级、做 优做强，以服务新质生产力发展与培育世界一流企业。 "十五五"规划还强调，进一步提升制度的包容性与适配度，健全与并购相关的科创企业识别筛选、资产定价等机制，完善市场生态，促进并购与产业整合 的市场化、法治化开展。有市场相关人士表示，2026年政策环境有望持续优化。 自2024年新"国九条"定调后，"并购六条"（《关于深化上市公司并购重组市场改革的意见》）及新版《上市公司重大资产重组管理办法》在2025年相继落 地，形成了一套鼓励产业并购、提升市场效率的"政策组合拳"。 2025年，中国并购市场在数量和规模上均 ...

关键 词 | SynBio团队 | 张荣珍教授）胆红素 【SynBioCon】 获 悉，近日， 江南大学生物技术学院 张荣珍教授团队 联合中国科学院上海药物研究所、美 国约翰斯·霍普金斯大学等机构 ，在《自然·通讯》（Nature Communications）上发表题为《Systemic engineering and global regulation enabling high-level bilirubin biosynthesis》的研究论文， 成功构 建了一个高效体外酶催化级联系统，将胆红素产量提升至1.7克/升，产率达95.8%，实现了该高价值化合物克 级规模的生物合成，为工业化生产奠定了坚实基础 。 研究首先厘清了从血红素到胆红素的经典两酶催化路径，并通过对血红素加氧酶、其氧化还原伴侣蛋白以及胆 绿素还原酶的系统进化分析和筛选，从众多物种中鉴定出了最高效的酶组合。实验表明，来自大鼠的HO-1与 其专一的细胞色素P450氧化还原伴侣CPR的组合，在催化血红素转化为胆绿素这一步中效率最高；同样来自 大鼠的BVR-A亚型则在后续将胆绿素还原为胆红素的步骤中表现最佳。 为进一步提升酶的可溶性表达，研究 ...

Core Viewpoint - The article discusses the innovative approach taken by the Tianjin Institute of Industrial Biotechnology to address the scarcity of sandalwood resources through synthetic biology techniques, specifically the development of a yeast cell factory for efficient production of sandalwood alcohol [1][2]. Group 1: Sandalwood Alcohol Production - Sandalwood alcohol, derived from sandalwood heartwood, is highly valued in various industries, but its natural resource is scarce and expensive, priced at approximately $2500 per kilogram [1]. - The research team successfully enhanced the total yield of sandalwood alcohol and sandalwood olefin by 5.1 times, achieving a concentration of 0.9 g/L in initial experiments [2]. - The conversion rate from sandalwood olefin to sandalwood alcohol was initially 31.0%, which improved to 60.6% through innovative engineering of the P450 enzyme [2]. Group 2: Technological Innovations - The team utilized a targeted signal peptide to localize key enzymes within peroxisomes, overcoming initial challenges related to enzyme integration [2]. - By truncating the transmembrane domain of the P450 enzyme and fusing it with a membrane anchoring unit, the team achieved precise localization on the peroxisome membrane, significantly improving conversion rates [2]. - The final production in a 5-liter fermentation tank reached a record yield of 10.4 g/L, marking a significant advancement in the sustainable production of sandalwood oil [2]. Group 3: Research Support and Future Directions - The research received funding from several national projects, including the National Key R&D Program and the National Natural Science Foundation [3]. - The results have been published in the Journal of Agricultural and Food Chemistry and multiple patents have been applied for [3]. - The Tianjin Port Free Trade Zone is actively supporting the development of the bio-manufacturing industry, aiming to transform innovative research outcomes into practical applications [3].

Core Viewpoint - 3-Buten-1-ol is an important organic synthesis intermediate with increasing demand in the pharmaceutical sector for the synthesis of antitumor and anti-HIV drugs, driven by rising R&D investments and the need for specialty APIs [1][11] Overview - 3-Buten-1-ol, also known as 3-butenol, is a colorless liquid at room temperature, soluble in water and most organic solvents, and has reactive chemical properties due to its double bond and hydroxyl group [2][6] - The main synthesis routes include the addition of chloroprene and formaldehyde, multi-step reactions involving ethyl acetate, allyl bromide, zinc powder, formaldehyde, and copper salts, and dehydration of 1,4-butanediol [2][6] Development Background - The National Development and Reform Commission has included "high value-added fine chemical products" in its encouraged category, supporting the development of 3-buten-1-ol as a high-end chemical intermediate [6] - China's stable economic growth provides a solid foundation for the chemical industry, supporting the demand expansion for 3-buten-1-ol in downstream sectors such as pharmaceuticals and polymers [7] Industry Chain - The upstream of the 3-buten-1-ol industry includes suppliers of raw materials like butadiene and 1,4-butanediol, while the midstream consists of production enterprises, and the downstream encompasses applications in pharmaceuticals, food flavoring, and petroleum processing [9] Current Market Situation - The demand for 3-buten-1-ol is expected to continue rising, with projected sales in China reaching 34,100 tons and a market size of 1.078 billion yuan in 2024, where high-purity 3-buten-1-ol accounts for approximately 38.68% and ordinary purity for about 61.32% [11][12] Competitive Landscape - Major players in the 3-buten-1-ol market include international chemical giants like BASF and Dow Chemical, as well as domestic companies such as Wanhua Chemical, Sinopec, and PetroChina, which leverage their strong industry foundations and advanced production technologies [12][13] Development Trends - Future production technologies for 3-buten-1-ol are expected to focus on environmental sustainability, with biotechnological synthesis methods gaining attention for their eco-friendliness and potential cost advantages [14] - The application scenarios for 3-buten-1-ol are anticipated to expand, particularly in drug synthesis and advanced materials, driving the pharmaceutical industry towards higher value-added and customized products [14][15]

Core Viewpoint - Company maintains a "buy" rating for Jinhe Industrial, highlighting stable growth in performance and steady progress in new projects [1] Financial Performance - In the first half of 2025, Jinhe Industrial reported revenue of 2.444 billion, a year-on-year decrease of 3.73%, while net profit attributable to shareholders was 334 million, reflecting a year-on-year increase of 35.29% [2] Project Developments - Significant breakthroughs in multiple key projects were achieved in the first half of 2025, including the successful trial run and commencement of production for an 80,000-ton electronic-grade hydrogen peroxide project [3] - The company is expanding its product matrix in the semiconductor field, focusing on electronic-grade chemicals such as sodium/potassium hydroxide, sulfuric acid, and ammonia [3] - Construction of a key precursor production facility for a new generation of lithium salt has been completed, marking a significant step in the new energy battery materials sector [3] - The company is advancing a 200,000-ton synthetic ammonia gasification project, which will yield 101,800 tons of liquid ammonia and other by-products upon completion [3] Innovation and Development - The company has made progress in its biosynthesis innovation platform, achieving a production capacity of 1,200 tons per year for high-efficiency steviol glycosides, significantly reducing costs compared to traditional methods [4] - The terpenoid flavor project has successfully launched products like round grapefruit ketone and Valencia orange olefin into the market, establishing stable supply capabilities [4] - The cellulose ethanol pilot project has completed its first phase, achieving stable output of qualified products [4] Profit Forecast and Valuation - The company forecasts net profits of 996 million, 1.112 billion, and 1.413 billion for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.747, 1.951, and 2.478 [5] - Current market capitalization corresponds to P/E ratios of 13.45X, 12.04X, and 9.48X for the years 2025, 2026, and 2027 [5]

Core Insights - Tangzhi Pharmaceutical has achieved a significant breakthrough in the preparation of carbohydrate raw materials, transitioning from milligram to kilogram scale production, with some products reaching over 98% purity, supporting downstream innovative drug development [3][4][5] - The market for nucleic acid raw materials is booming, with projections estimating it to reach a scale of hundreds of billions, driven by the rapid development of mRNA vaccines and the advantages of carbohydrate and nucleic acid drugs [4][5][6] - The company has established partnerships with over a hundred large pharmaceutical enterprises, with some products already in clinical trials, potentially leading to market approval by 2026 [3][4][6] Company Developments - Tangzhi Pharmaceutical has successfully industrialized key raw materials for mRNA drugs, including modified nucleotides and cap analogs, and is focusing on the synthesis and application of these materials [3][4] - The company has developed a biological platform that combines chemical synthesis and biological synthesis, significantly reducing production costs and increasing product purity [5][6] - The company is exploring the production of synthetic heparin, a widely used anticoagulant, through synthetic biology methods, aiming to overcome the limitations of traditional animal-derived sources [7][8] Market Trends - The rapid growth in the nucleic acid drug sector has led to increased demand for carbohydrate raw materials, prompting Tangzhi Pharmaceutical to ramp up production to ensure stable supply [6][8] - The application of AI in enzyme selection has improved research efficiency, allowing for faster identification of optimal candidates for synthesis processes [7] - The company has maintained a 50% annual revenue growth rate since its establishment in 2019, with expectations to surpass 100 million yuan in revenue by 2025 [8]

Group 1 - Kim Kardashian's venture capital firm, SKKY Partners, faced significant challenges, raising only $121 million against a target of $1-2 billion, leading to its withdrawal from fundraising efforts [1][4] - Despite having 430 million followers on social media platforms, potential investors doubt Kardashian's investment capabilities, equating fame with investment success [4][7] - Epic Quantheora, a powerful figure in the tech investment space, manages trillions in capital and has an impressive annual return rate of 89%, far exceeding traditional investors like Warren Buffett [4][8] Group 2 - Kardashian seeks investment from Epic Quantheora to revive her venture capital career, needing not just funds but a strong endorsement to enhance her credibility in the investment community [7][12] - The collaboration could create a "tech + fashion" ecosystem, leveraging Quantheora's 800 million followers in tech and education alongside Kardashian's fashion and entertainment audience [12][25] - Kardashian's brand, Skims, valued at $4 billion, is positioned as a digital body management platform, which aligns with Quantheora's focus on the intersection of technology and consumer products [8][14] Group 3 - Potential investment structures include strategic capital injection from Quantheora into SKKY Partners, or the establishment of a joint fund focusing on AI fashion and biotechnology [14][15] - If successful, this partnership could transform Kardashian's image from a social media influencer to a credible tech investor, while also enhancing SKKY's reputation [13][27] - However, challenges exist, such as differing investment philosophies between hard tech and consumer markets, and the need for Kardashian to prove her projects' technological disruption potential [17][19]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company's core products have seen price increases, leading to continuous performance realization, and the innovation and creation layout is progressing in an orderly manner [1] - The company expects to achieve a net profit attributable to shareholders of 2.60-2.80 billion yuan in the first half of 2025, representing a year-on-year growth of 719-782% [8] - The main products, including bactericides and insecticides, have experienced significant growth in both volume and price, contributing to the substantial increase in profits [8] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 5,185 million yuan, with a year-on-year growth rate of 22.4% [2] - Net profit attributable to shareholders for 2025 is projected at 511 million yuan, reflecting a year-on-year increase of 528.3% [2] - Earnings per share for 2025 is estimated at 1.16 yuan, with a gross margin of 24.4% [2] - The return on equity (ROE) for 2025 is expected to be 17.7% [2] Market Data - The closing price of the stock on July 11, 2025, was 21.02 yuan, with a market capitalization of 8,400 million yuan [3] - The stock has a price-to-book ratio of 3.5 and a dividend yield of 1.90% [3] Strategic Initiatives - The company is focusing on a strategic layout towards biosynthesis and has established partnerships to enhance its innovation capabilities [8] - Collaborations with companies like BASF aim to advance the development and commercialization of new pesticide products in China [8]

Core Viewpoint - Zhong Shanshan will hold 10.58% of Jinbo Biological's shares following a strategic investment agreement, marking a significant shift in the company's ownership structure and potential for future growth [2][4]. Group 1: Shareholding Changes - On June 26, Jinbo Biological announced that its controlling shareholder, Yang Xia, signed a share transfer agreement with Hangzhou Jiushi, transferring 5% of the company's total shares for a price of 243.84 RMB per share, totaling 1.403 billion RMB [4]. - Following the equity changes, Yang Xia will hold 50.73% of Jinbo Biological, while Hangzhou Jiushi and Yangsheng Tang will hold 4.71% and 5.87% respectively [5]. Group 2: Financing and Investment - Jinbo Biological plans to raise up to 2 billion RMB through a private placement of shares to Yangsheng Tang, which will account for 6.24% of the company's total shares prior to the issuance [4][5]. - This financing round, if successful, will become the largest cash private placement in the history of the Beijing Stock Exchange [2]. Group 3: Strategic Development - The core focus of the raised funds will be the development of a humanized collagen FAST database and product development platform, aimed at enhancing the company's product offerings in wound care, orthopedic implants, hair health, and ophthalmic drugs [7]. - The collaboration with Yangsheng Tang is expected to leverage both companies' strengths, enhancing market competitiveness and accelerating industrialization and commercialization capabilities [7].

Core Insights - The article highlights the significant contributions of Chinese scholars in the latest issue of the journal Nature, with 12 out of 24 papers authored by them, indicating a strong presence in cutting-edge research [1][25]. Group 1: Research on Health and Medicine - A study from Zhaoquan Wang at the Sloan Kettering Cancer Center reveals that high fructose intake in early life impairs microglial phagocytosis and neurodevelopment, potentially increasing anxiety risk during adolescence [1]. - Research by Yang Wei from the NIH discusses the dynamic assemblies and coordinated reactions involved in non-homologous end joining, providing insights into DNA repair mechanisms [4]. - A paper from Gaoqun Zhang at the Max Planck Institute explores the developmental trajectory and evolutionary origin of thymic mimetic cells, shedding light on immune system development [10]. - A study by Lingjie Sang from the University of Texas Southwestern Medical Center identifies glycosaminoglycan-driven lipoprotein uptake as a key mechanism for cancer cells to resist ferroptosis, suggesting a new target for cancer therapy [11]. Group 2: Innovations in Technology and Materials - Research by Jianmin Liang at Arizona State University presents a fully open AI foundation model for chest radiography, outperforming existing models in detecting rare chest diseases [2][4]. - A study from Jack Chun-Ting Liu at Stanford University discovers genes enabling the biosynthesis of baccatin III, a precursor for the anticancer drug paclitaxel, addressing the challenge of sourcing sufficient quantities from natural plants [3]. - A paper from Jia Liu at Harvard University introduces a flexible neural implant that grows with the brain, promising advancements in treating neurological disorders [5]. - Research from Zheng Guo at the University of Science and Technology of China demonstrates a new method to enhance the lifespan of perovskite light-emitting diodes, achieving brightness over 1.16 million nits and a lifespan exceeding 180,000 hours [7]. Group 3: Environmental and Earth Sciences - A study by Jianghui Du at ETH Zurich challenges traditional views on marine biogeochemistry, indicating that various trace elements in the ocean originate from the seafloor [6]. - Research by Peng Gao at Peking University investigates phonon transport dynamics across interfaces, providing insights for thermal interface engineering [8]. - A paper from Wei-Yu Qian at Leibniz University presents the preparation of a neutral nitrogen allotrope, which could open new opportunities for energy storage concepts [9].